Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796527 | 0.83 | ALDH1A1 (0.37) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL4590231 | 0.79 | CA1 (0.42) | CYP1A2TSHRALDH1A1CA1CA2 | |
| SCHEMBL5029845 | 0.75 | CYP1A2 (0.47) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL366710 | 0.71 | RAPGEF4 (0.39) | CYP2A6CYP1A2TSHRALDH1A1CA1 | |
| SCHEMBL1317465 | 0.71 | CYP2A6 (0.43) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL1315331 | 0.71 | CYP2A6 (0.43) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL29456798 | 0.70 | TRPA1 (0.42) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL1022119 | 0.70 | TRPA1 (0.42) | CYP2A6CYP1A2ACHETSHRALDH1A1 | |
| SCHEMBL29881812 | 0.69 | — | — | |
| SCHEMBL959600 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2021012478-A1 | HYDROGENATION ANNULE [12] AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| WO-2021012479-A1 | HYDROGENATED CYCLIC [8] AROMATIC HYDROCARBON COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | claimed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | claimed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4621028-A1 | FLUORESCENCE RECOVERY IN NANOGRAPHENE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12409238-B2 | Silicone-based dyes with short wavelength infrared absorption and emission and methods for making and using the same | UNIV MISSISSIPPI (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025000671-A1 | SULFONAMIDE COMPOUND AND USE THEREOF | 凌科药业(杭州)有限公司 | 2025-01-02 | — | — | WO | disclosed |
| WO-1999009845-A1 | IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5654441-A | Synthesis of 1,3-oxathiolane sulfoxide compounds | UNIROYAL CHEMICAL LTD./LTEE (CA) | 1997-08-05 | — | — | US | disclosed |
| US-4124751-A | PHENYLMAGNESIUM HALIDE AS INITIATOR | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-07 | — | — | US | disclosed |
| US-3965112-A | Imidazoline derivatives | JOHN WYETH & BROTHER LIMITED (EN) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409238-B2 | Silicone-based dyes with short wavelength infrared absorption and emission and methods for making and using the same | SMARCB1, SMARCD1, SMARCA5 | CYP2A6 3887/4885CYP1A2 3175/4885ACHE 992/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | CYP2A6 355/4885CYP1A2 394/4885ACHE 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.